Vitamin D Status and Efficacy of Vitamin D Supplementation in Atopic Dermatitis: A Systematic Review and Meta-Analysis

Open AccessArticle

Nutrients 2016, 8(12), 789; doi:10.3390/nu8120789
Min Jung Kim ¹

,Soo-Nyung Kim ²

,Yang Won Lee ^1,3,* ,Yong Beom Choe ^1,3

 andKyu Joong Ahn ^1,3

¹Department of Dermatology, Konkuk University School of Medicine, Seoul 05030, Korea²Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul 05030, Korea³Research Institute of Medical Science, Konkuk University, Seoul 05030, Korea

Abstract
Recent literature has highlighted the possible role of vitamin D in atopic dermatitis (AD), and that vitamin D supplementation might help to treat AD. This study determined the relationship between vitamin D level and AD, and assessed the efficacy of vitamin D supplementation. We searched the MEDLINE, EMBASE, and Cochrane databases up to May 2015. Observational studies and randomized controlled trials were included based on the available data on the serum 25-hydroxyvitamin D (25(OH)D) level and quantified data available for severity assessed using the Scoring Atopic Dermatitis (SCORAD) index or Eczema Area and Severity Index (EASI) score.

Targeting integrin α5β1 ameliorates severe airway hyperresponsiveness in experimental asthma

Aparna Sundaram,1 Chun Chen,1 Amin Khalifeh-Soltani,2 Amha Atakilit,1 Xin Ren,1 Wenli Qiu,1 Hyunil Jo,3 William DeGrado,3 Xiaozhu Huang,1 and Dean Sheppard1

First published December 5, 2016 - More info

Research Article Muscle biology Pulmonology

Abstract

Treatment options are limited for severe asthma, and the need for additional therapies remains great. Previously, we demonstrated that integrin αvβ6-deficient mice are protected from airway hyperresponsiveness, due in part to increased expression of the murine ortholog of human chymase. Here, we determined that chymase protects against cytokine-enhanced bronchoconstriction by cleaving fibronectin to impair tension transmission in airway smooth muscle (ASM).

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

April W. Armstrong, MD, MPHPress enter key for correspondence informationPress enter key to Email the author

, 

Michael P. Siegel, PhD

, 

Jerry Bagel, MD

, 

Erin E. Boh, MD, PhD

, 

Megan Buell

, 

Kevin D. Cooper, MD

, 

Kristina Callis Duffin, MD, MS

, 

Lawrence F. Eichenfield, MD

, 

Amit Garg, MD

, 

Joel M. Gelfand, MD, MSCE

, 

Alice B. Gottlieb, MD, PhD

, 

John Y.M. Koo, MD

, 

Neil J. Korman, MD, PhD

, 

Gerald G. Krueger, MD

, 

Mark G. Lebwohl, MD

, 

Craig L. Leonardi, MD

, 

Arthur M. Mandelin, MD, PhD

, 

M. Alan Menter, MD

, 

Joseph F. Merola, MD, MMSC

, 

David M. Pariser, MD

, 

Ronald B. Prussick, MD, FRCP

, 

Caitriona Ryan, MD

, 

Kara N. Shah, MD

, 

Jeffrey M. Weinberg, MD

, 

MaryJane O.U. Williams, MD

, 

Jashin J. Wu, MD

, 

Paul S. Yamauchi, MD, PhD

, 

Abby S. Van Voorhees, MD

Open Access

DOI: http://dx.doi.org/10.1016/j.jaad.2016.10.017

Article Info

• Abstract

• Full Text
• Images
• References

Background

An urgent need exists in the United States to establish treatment goals in psoriasis.

Objective

We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice.

Methods

The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds.

Applying Multiple Data Collection Tools to Quantify Human Papillomavirus Vaccine Communication on Twitter

Journal of Medical Internet Research 
Vol 18, No 12 (2016): December

• Article
• Cited By (0)
• Tweetations (6)
• Metrics

Original Paper

• Philip M Massey^1*, MPH, PhD ; 
• Amy Leader^2*, MPH, DrPH ; 
• Elad Yom-Tov^3*, MSc, PhD ; 
• Alexandra Budenz^1*, MA ; 
• Kara Fisher^4*, MPH ; 
• Ann C Klassen^1*, PhD 

¹Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States

²Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States

³Microsoft Research Israel, Herzeliya, Israel

⁴Department of Biostatistics and Epidemiology, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States

*all authors contributed equally

ABSTRACT

Background: Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. There are several vaccines that protect against strains of HPV most associated with cervical and other cancers. Thus, HPV vaccination has become an important component of adolescent preventive health care. As media evolves, more information about HPV vaccination is shifting to social media platforms such as Twitter. Health information consumed on social media may be especially influential for segments of society such as younger populations, as well as ethnic and racial minorities.

An eHealth Project on Invasive Pneumococcal Disease: Comprehensive Evaluation of a Promotional Campaign

Journal of Medical Internet Research

Published on 02.12.16 in Vol 18, No 12 (2016): December

Donatella Panatto^1*, PhD ; 

Alexander Domnich^1*, MD ; 

Roberto Gasparini¹, MD ; 

Paolo Bonanni², MD ; 

Giancarlo Icardi¹, MD ; 

Daniela Amicizia¹, MD ; 

Lucia Arata¹, MD ; 

Stefano Carozzo¹, MD ; 

Alessio Signori¹, PhD ; 

Angela Bechini², PhD ; 

Sara Boccalini², PhD 

¹Department of Health Sciences, University of Genoa, Genoa, Italy

²Department of Health Sciences, University of Florence, Florence, Italy

*these authors contributed equally

ABSTRACT

Background: The recently launched Pneumo Rischio eHealth project, which consists of an app, a website, and social networking activity, is aimed at increasing public awareness of invasive pneumococcal disease (IPD). The launch of this project was prompted by the inadequate awareness of IPD among both laypeople and health care workers, the heavy socioeconomic burden of IPD, and the far from optimal vaccination coverage in Italy, despite the availability of safe and effective vaccines.

Severe asthma: anti-IgE or anti-IL-5?

Go to:

Abstract

Eur Clin Respir J. 2016; 3: 10.3402/ecrj.v3.31813.

Published online 2016 Nov 7. doi:  10.3402/ecrj.v3.31813

PMCID: PMC5102127

Evgenia Papathanassiou,¹ Stelios Loukides,¹ and Petros Bakakos^2,*

Author information ► Article notes ► Copyright and License information ►

Abstract

Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced quality of life and poor asthma control as ordinary treatment regimens remain inadequate. Difficulty in managing severe asthma derives partly from the multiple existing phenotypes and our inability to recognise them. Though the exact pathogenetic pathway of severe allergic asthma remains unclear, it is known that numerous inflammatory cells and cytokines are involved, and eosinophils represent a key inflammatory cell mediator. Anti-IgE (omalizumab) and anti-IL-5 (mepolizumab) antibodies are biological agents that interfere in different steps of the Th2 inflammatory cascade and are licensed in severe asthma.

Dr. Neha Patel reviews the mysterious condition known as exercise-induced anaphylaxis

Introduction to Immunology - ACAAI COLA

Dr. Nakita Raje presents an introduction to immunology. This is a gradulate-level immunology review for immunology fellows

Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis

PLoS One. 2016 Nov 22; 11(11):e0166833. 

doi: 10.1371/journal.pone.0166833. eCollection 2016.

Wang FP1, Liu T1, Lan Z2, Li SY3, Mao H1.

Author information

Abstract

BACKGROUND:

Recent trials have assessed the efficacy and safety of novel monoclonal antibodies such as reslizumab and benralizumab. However, the overall efficacy and safety anti-interleukin (IL) 5 treatment in asthma have not been thoroughly assessed.